Severe fever with thrombocytopenia syndrome (SFTS) is an emerging viral hemorrhagic fever (VHF) caused by SFTS virus (SFTSV). The disease was first discovered in China in 2010 and is mainly transmitted by tick bite and occasionally from person-to-person spread via SFTSV-infected blood or fluid \[[@CIT0001], [@CIT0002]\]. By the end of 2018, more than 8000 clinically diagnosed SFTS patients were reported in China \[[@CIT0003]\], and over 1000 cases were reported from Japan \[[@CIT0004]\], South Korea \[[@CIT0005]\], and Vietnam \[[@CIT0006]\], with a case fatality rate ranging from 5% \[[@CIT0003]\] to 30% \[[@CIT0002]\]. Another important VHF that is life threatening among large populations is hemorrhagic fever with renal syndrome (HFRS), which is caused by hantavirus and is often carried and transmitted by rodents \[[@CIT0007]\]. Although HFRS cases occur worldwide, approximately 90% of the cases were reported in China, Japan, and South Korea \[[@CIT0008], [@CIT0009]\], which shows a highly similar geographic distribution to that of SFTS. Epidemiologically, both SFTS and HFRS are prevalent in rural areas, and farmers and outsiders are susceptible to infection through high-risk exposure to vector or host. Clinically, the 2 VHFs shared common features, with atypical and indistinguishable febrile disease observed at acute infection, subsequently followed by a critical or recovery phase. For those with adverse disease outcomes, both infections might rapidly progress into severe illness, which is characterized by hemorrhagic fever or multiple organ dysregulation. All of these features made differential diagnosis difficult in the endemic regions where both diseases are prevalent. A recent study reported the discovery of 4 patients with SFTSV infection out of 55 hantavirus-negative patients in Shandong Province, a long existing endemic region for HFRS \[[@CIT0010]\]. We hypothesize that, similar to SFTS, HFRS can be misdiagnosed. In this report, we conducted a retrospective study in SFTS-endemic and HFRS-endemic regions, respectively, to identify the misdiagnosis of 2 VHF diseases and to attain differential diagnosis based on complete and detailed clinical data recording.

METHODS {#s1}
=======

The study was performed in 3 regions, where both SFTS and HFRS have been reported ([Supplemental Figure 1](#sup1){ref-type="supplementary-material"}). The sera sample and epidemiological database of clinically diagnosed HFRS patients had been collected from the Liaoning Center for Disease Control and Prevention (CDC) and Qingdao CDC. The clinically diagnosed patients and laboratory-confirmed patients had been defined by the criteria for SFTS \[[@CIT0011]\] and HFRS \[[@CIT0012]\], respectively, that was released by National Health Commission of the People's Republic of China (also see the [Supplemental Material and Methods](#sup8){ref-type="supplementary-material"}). The sera sample and epidemiological database of clinically diagnosed SFTS patients had been collected from Liaoning CDC and the People\'s Liberation Army 990 hospital in Xinyang city, Henan province. All sera samples were collected immediately after hospital admission and tested for hantavirus and SFTSV infection at the acute phase of illness. Data regarding demographic, epidemiological, and pretreatment clinical information were recorded by using a standard questionnaire released by China CDC.

In the current study, by using the available sera sample, we retested clinically diagnosed HFRS patients for SFTSV ribonucleic acid by applying real-time reverse-transcription polymerase chain reaction (RT-PCR) \[[@CIT0002]\] and anti-SFTSV immunoglobulin (Ig)M antibody by applying immunofluorescence assay (IFA), and we retested clinically diagnosed SFTS patients for hantavirus by applying real-time RT-PCR and anti-hantavirus IgM antibody by using a commercial ELISA Kit (Wantai Biological Pharmacy, Beijing, China) ([Supplemental Material and Methods](#sup8){ref-type="supplementary-material"}). The available epidemiological and clinical datasets were retrospectively used for the current analysis. The study protocol was approved by the Review Board of Beijing Institute of Microbiology and Epidemiology. The SFTS and HFRS differentiation was performed using logistic regression model, and the differential factors were identified by using the classification tree with a Chi-square Automatic Interaction Detection (CHAID) model. Receiver operating characteristic (ROC) curves were constructed for evaluation of the scoring model. A 2-sided *P* \< .05 was considered statistically significant. All analyses were performed using STATA 14.0 (Stata Corp LLP, College Station, TX) and SPSS version 22 (IBM Corp., Armonk, NY).

RESULTS {#s2}
=======

A total of 1546 patients were enrolled. In the SFTS-endemic region, 943 clinically diagnosed SFTS patients were screened, and 588 (62.4%) were positive for SFTSV infection, including 5 (0.9%) with hantavirus infection (coinfection group). Among the remaining 355 (38.6%) SFTSV-negative patients, 21 (5.9%) were positive for hantavirus infection (defined as the misdiagnosed group) ([Supplemental Table 1](#sup4){ref-type="supplementary-material"}). In comparison with SFTSV-positive patients, the misdiagnosed patients had significantly younger age, shorter interval from disease onset to hospital admission, higher frequency of mouse contact, and lower frequency of tick bite (all *P* \< .05). Abdominal pain, nausea, and enlarged lymph nodes were less frequently seen among the misdiagnosed patients compared with the SFTSV-positive patients (all *P* \< .05). For 2 hallmark laboratory features of SFTS, leukopenia was underrepresented in the misdiagnosed patients (*P* \< .001), whereas thrombocytopenia was seen with comparable frequency ([Supplemental Table 1](#sup4){ref-type="supplementary-material"}).

In the HFRS-endemic regions, 603 clinically diagnosed HFRS patients were screened, and 348 (57.7%) were positive for hantavirus infection, including 4 (1.1%) with SFTSV infection (coinfection group). Among the remaining 255 (42.3%) hantavirus-negative patients, 8 (3.1%) were positive for SFTSV infection (misdiagnosed group). The misdiagnosed SFTS patients had older age, higher frequency of tick bite, higher body temperature, and higher presence of enlarged lymph nodes, thrombocytopenia, and leukopenia (all *P* \< .05) ([Supplemental Table 2](#sup5){ref-type="supplementary-material"}).

The hantavirus-SFTSV coinfection rate (0.6%, 9 of 1546) was lower than the expected rate that was calculated from SFTSV single infection rate multiplied by the hantavirus single infection rate, ie, 36.2% multiplied by 24.2%, indicating a lower tendency of coinfection between the 2 pathogens. The coinfection group did not reveal significantly higher proportions of clinical features than the SFTS alone or HFRS alone group ([Supplemental Table 3](#sup6){ref-type="supplementary-material"}), indicating no more serious outcome originated from coinfection, which might be biased by the small sample size.

To attain clinical differentiation between 2 diseases, the laboratory-confirmed SFTS (n = 591) and HFRS patients (n = 365) were grouped for the evaluation of 33 variables regarding demographic, epidemiological, and clinical characteristics ([Table 1](#T1){ref-type="table"}). Most of the variables displayed significant differences between 2 groups, and 18 significant variables showed area under the curve (AUC) \>0.600 and were further entered into the multiple logistic regression model to attain better discrimination power. On the ROC curve obtained from the model, the AUC was 0.985 (95% confidence interval \[CI\], 0.979--0.992), with 92.6% (95% CI, 89.4%--95.1%) sensitivity and 95.4% (95% CI, 93.4%--97.0%) specificity ([Supplemental Figure 2](#sup2){ref-type="supplementary-material"}). Patients of younger age that had mouse contact history, clinical presence of blush, low back pain, and higher level of white blood cell (WBC) counts (≥4.74 × 10^9^/L) were significantly associated with hantavirus infection rather than SFTSV infection. Patients of older age that had tick bite history, presented with diarrhea, had enlarged lymph nodes, and had lower level of WBC counts (\<4.74 × 10^9^/L) were significantly associated with SFTSV infection rather than hantavirus infection ([Supplemental Table 4](#sup7){ref-type="supplementary-material"}). The classification tree was generated based on the significant variables in the multiple logistic analysis. Patients with WBC ≤2.7 × 10^9^/L without mouse contact history or low back pain (Node 19), or patients with WBC of 2.7 × 10^9^/L--3.4 × 10^9^/L and enlarged lymph nodes (Node 10) were classified as SFTS patients. Patients with WBC of 7.6 × 10^9^/L--8.4 × 10^9^/L (Node 14) and low back pain or patients with both WBC \>8.4 × 10^9^/L and mouse contact history (Nodes 16 and Node 18) were classified as HFRS patients ([Supplemental Figure 3](#sup3){ref-type="supplementary-material"}).

###### 

The Basic and Clinical Differentiation Between the Laboratory-Confirmed SFTS and HFRS Patients

  Characteristics                              SFTS (n = 591)   HFRS (n = 365)   P value     AUC
  -------------------------------------------- ---------------- ---------------- ----------- -------
  Age, year, mean ± SD                         62 ± 12          46 ± 14          \<.001^a^   0.812
   \<45                                        55 (9.3)         161 (44.1)       \<.001^b^   0.784
   45-60                                       167 (28.3)       152 (41.6)                   
   ≥60                                         369 (62.4)       52 (14.3)                    
  Sex, male                                    279 (47.2)       269 (73.7)       \<.001^b^   0.633
  Days from onset to admission, median (IQR)   5 (3-6)          4 (2-6)          \<.001^c^   0.433
  Recent contact with                                                                        
   Mouse                                       31 (5.3)         164 (44.9)       \<.001^b^   0.698
   Mosquito (n = 461)                          20 (9.0)         6 (2.5)          .003^b^     0.533
   Tick                                        151 (25.6)       2 (0.6)          \<.001^d^   0.625
   Mice faeces                                 10 (4.6)         2 (0.8)          .016^d^     0.519
  **Clinical Manifestation, n (%)**                                                          
  Headache                                     187 (31.6)       253 (69.3)       \<.001^b^   0.688
  Highest temperature, ℃, mean ± SD            38.9 ± 0.6       39.0 ± 0.6       .010^a^     0.543
  Low back pain (n = 634)                      81 (28.9)        210 (59.3)       \<.001^b^   0.652
  Orbital pain (n = 634)                       17 (6.1)         100 (28.3)       \<.001^b^   0.611
  Arthralgia                                   90 (15.2)        92 (25.2)        \<.001^b^   0.550
  Pantalgia                                    406 (68.7)       122 (33.4)       \<.001^b^   0.676
  Nausea                                       427 (72.3)       185 (50.7)       \<.001^b^   0.608
  Vomiting                                     213 (36.0)       112 (30.7)       .089^b^     0.527
  Abdominal pain                               158 (26.7)       84 (23.0)        .199^b^     0.519
  Diarrhea                                     224 (37.9)       59 (16.2)        \<.001^b^   0.609
  Blush (n = 634)                              28 (10.0)        158 (44.6)       \<.001^b^   0.673
  Neck red (n = 634)                           19 (6.8)         114 (32.2)       \<.001^b^   0.627
  Chest red (n = 634)                          10 (3.6)         88 (24.9)        \<.001^b^   0.606
  Hemoptysis                                   7 (1.2)          3 (0.8)          .750^d^     0.502
  Conjunctival congestion                      42 (7.1)         107 (29.3)       \<.001^b^   0.611
  Eyelids swelling (n = 634)                   12 (4.3)         48 (13.6)        \<.001^b^   0.546
  Jaundice                                     3 (0.5)          2 (0.6)          1.000^d^    0.500
  Enlarged lymph nodes                         241 (40.8)       4 (1.1)          \<.001^d^   0.698
  Hepatosplenomegaly (n = 634)                 3 (1.1)          3 (0.9)          1.000^d^    0.501
  Oliguria (n = 634)                           24 (8.6)         71 (20.1)        \<.001^b^   0.557
  Mucosal hemorrhage                           86 (14.6)        61 (16.7)        .368^b^     0.511
  Rash                                         7 (1.2)          2 (0.6)          .495^d^     0.569
  Petechial or bruise                          72 (12.2)        30 (8.2)         .054^b^     0.503
  **Outcome**                                                                    \<.001^b^   0.500
   Cure                                        484 (81.9)       351 (96.2)                   
   Deterioration                               96 (16.2)        11 (3.0)                     
   Fatal when discharged from hospital         11 (1.9)         3 (0.8)                      
  **Laboratory Parameters on Admission**                                                     
  White blood cells, ×10^9^/L, median (IQR)    2.3 (1.6-3.4)    8.7 (5.6-14.9)   \<.001^c^   0.930
   \<4                                         474 (80.2)       37 (10.1)        \<.001^b^   0.871
   4-10                                        105 (17.8)       220 (60.3)                   
   ≥10                                         12 (2.0)         108 (29.6)                   
  Platelet counts, ×10^9^/L, median (IQR)      58 (40-81)       53 (34-86)       .269^c^     0.468
   \<50                                        212 (35.9)       112 (30.7)       .247^b^     0.528
   50-100                                      312 (52.8)       206 (56.4)                   
   ≥100                                        67 (11.3)        47 (12.9)                    
  Positive urine protein (n = 694)             261 (58.1)       203 (82.9)       \<.001^b^   0.624
  Prolonged coagulation time (n = 433)         140 (43.1)       27 (25.0)        .001^b^     0.590

Abbreviations: AUC, area under the curve; HFRS, hemorrhagic fever with renal syndrome; IQR, interquartile range; SD, standard deviation; SFTS, severe fever with thrombocytopenia

syndrome.

NOTE: The variables with AUC\>0.600 were further entered for multivariate analysis.

^a^ *t* test.

^b^χ2 test.

^c^Non-parametric test.

^d^Fisher exact test.

DISCUSSION {#s3}
==========

In rural regions where both HFRS and SFTS circulate, a common dilemma in diagnosis is the lack of molecular or immunological assay in clinical medical care. The current gold standard for diagnosis is IFA or enzyme-linked immunosorbent assay test or molecular test by PCR \[[@CIT0010]\], whereas their widespread use is limited due to lack of instrument or technical expertise in rural areas where disease circulated. Although the case definition of SFTS or HFRS defined by classic clinical features is sufficiently sensitive to capture most of the likely cases, there are other patients with atypical manifestation that was missed by the clinical definition. In this study, we provided evidence showing that a certain proportion of hantavirus infection was found in patients who were initially diagnosed with SFTS, and vice versa a certain proportion of SFTSV infection existed in patients treated for HFRS. The presence of low back pain, orbital pain, neck red and chest red, and headache, which are considered to be typical characteristics of HFRS, was also observed in SFTSV-infected patients. Likewise, thrombocytopenia, as one of the hallmarks of SFTS, was also frequently and comparably recorded in HFRS patients. Despite these atypical features, other indicators, including frequency of previous tick/mouse contact, enlarged lymph nodes, and WBC ≤3.4 × 10^9^/L, remained to be significantly different between 2 types of infections. Moreover, after taking into account these atypical cases, a model that made use of enlarged lymph nodes and WBC counts, together with the classic manifestations such as blush and low back pain, enabled adequate differential diagnosis between HFRS and SFTS in both endemic areas. Still, the effectiveness of the model needs to be evaluated by further clinical studies in other endemic regions.

CONCLUSIONS {#s4}
===========

This study had limitations that were inherent to retrospective study. Because SFTS viremia is known to wane quickly from 7 days postadmission \[[@CIT0013]\], some of the SFTSV infection might be missed by both loss of viremia and inadequate timing to develop IgM responses. We made no effort to determine the etiological agents of the remaining negative patients, because SFTS and HFRS were among the top list of endemic diseases with high case fatality. In particular, for SFTS disease, more attention and fear were caused because of its high case fatality and person-to-person transmission via human blood \[[@CIT0001], [@CIT0014]\]. In case of confirmed SFTSV infection at early illness, strict person protection measures should be adopted. Although there is currently no effective therapy for SFTS patients, several experimental therapies such as plasma exchange therapy \[[@CIT0015], [@CIT0016]\], intravenous Ig plus steroid \[[@CIT0017]\], and convalescent serum therapy \[[@CIT0018]\] might be beneficial if adopted at early stage of the disease. Therefore, the current findings might provide information to guide prevention measures and clinical practice in endemic regions where both diseases exist.
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Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
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